Abstract: Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.

Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality

Abstract: A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.

Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality

Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.

Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.

Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality